Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 February 2020 | Story Valentino Ndaba | Photo Stephen Collett
UFS official opening
Kovsies is on track with the firm foundation laid in previous years. 2020 is a year where visibility and impact is the key theme.

WATCH: Official Opening 2020

Tackling 2020 with rigour and vigour is the top priority for the University of the Free State’s agenda and it’s all systems go after a year of building a solid foundation. Prof Francis Petersen, UFS Rector and Vice-Chancellor, addressed staff in his official Opening speech at the Bloemfontein Campus on Friday 7 February 2020.

“The university is on track with what it set out to deliver in 2019” Prof Petersen shared the successes of 2019 with the audience and outlined his vision and plans for 2020 with visibility and impact as the key themes. 

Prof Petersen urged staff to work hand-in-hand to ensure an outcome that generations will inherit with pride. “We have our eyes firmly set on the far horizon, to ensure that we bestow an institution on the next generation that is different from the past, a place where every essence is in perpetual renewal. That means every one of us is smaller than the institution, and every one of us needs to lay a brick that builds a university that is different from the past, more impressive than the past, an institution that will grow constantly.” 

Setting the pace

As a frame of reference, Prof Petersen pointed to engagement, conversation, clear communication and decisive action to yield the type of environment in which we all want to work and study. “I can assure you that we will continue with that engagement, in a sphere of respect, tolerance for different views by always focusing on what the Integrated Transformation Plan (ITP) stands for – which is fairness and social justice.”

Reflecting on the year that was.


Prof Petersen reflected on 2019 as a year which focused on a return on investment delivery as it relates to the Strategic Plan, ITP, seven Vice-Chancellor’s projects, institutional and multi-stakeholder group and institutional Risk Register. These guiding documents laid a firm foundation for implementation processes to take place this year.

Leading the way

The Rector related some success stories which include the increased number of NRF-rated researchers. “In the area of student success, we are probably leading the country and our inputs are globally known.”

As a national leader on the infrastructural and student accommodation front, the Department of Higher Education, Science and Technology often consults the UFS for advice on how other institutions can adequately spend their infrastructure grants. Moving forward, the university also plans to partner more with national and international institutions of higher learning with the aim of strengthening research and innovation ties.

On inclusiveness and social cohesion

Pressing issues such as gender-based violence and xenophobia are constantly being tackled by the Unit for Institutional Change and Social Justice in collaboration with other academic and support services. These parties have conducted and developed critical conversations, position papers, and policies to guide the institution towards an inclusive and socially cohesive space which embraces the values of ubuntu and respect.

In closing, Prof Petersen reminded the university community of the crucial role each individual plays in building a bright future. “We must always remember that the UFS exists through its staff and students and should never let one of them feel neglected or unheard.” 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept